Home  |  Contact

Cellosaurus DiFi R2 Cetux (CVCL_A2BX)

[Text version]
Cell line name DiFi R2 Cetux
Accession CVCL_A2BX
Resource Identification Initiative To cite this cell line use: DiFi R2 Cetux (RRID:CVCL_A2BX)
Comments Population: Caucasian.
Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
Sequence variations
  • Mutation; HGNC; 583; APC; Simple; p.Glu443fs*16 (c.1328_1329delAA); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 583; APC; Simple; p.Glu1151Ter (c.3451G>T); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (from parent cell line).
Disease Colorectal carcinoma (NCIt: C2955)
Gardner syndrome (NCIt: C6728)
Gardner syndrome (ORDO: Orphanet_79665)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_6895 (DiFi)
Sex of cell Female
Age at sampling 46Y
Category Cancer cell line
Publications

PubMed=25623215; DOI=10.1158/1078-0432.CCR-14-2821
Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I., Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., Iglesias M., Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sanchez J., Dalmases A., Bellmunt J., De Fabritiis G., Rovira A., Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer.
Clin. Cancer Res. 21:2157-2166(2015)

Cross-references
Cell line databases/resources cancercelllines; CVCL_A2BX
Encyclopedic resources Wikidata; Q105506755
Polymorphism and mutation databases Cosmic; 2841362
Entry history
Entry creation12-Jan-2021
Last entry update05-Oct-2023
Version number5